Polypill Effects on Sub Clinical Atherosclerosis (PESCA) Trial (PESCA)
|Cardiovascular Disease||Drug: Polypill: Red Heart Pill Drug: Usual medication||Phase 3|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||PESCA - A Randomised Controlled Trial of a Cardiovascular Polypill Treatment Strategy Compared With Usual Care on Carotid Intima-media Thickness in Individuals at High Risk of Cardiovascular Disease|
- change in intima-media (artery wall) thickness in the common carotid artery [ Time Frame: from baseline to end of trial follow up (1-2 years) ]
- change in intima-media (artery wall) thickness and extent of atherosclerotic plaques in the carotid artery bifurcation [ Time Frame: from baseline to end of trial follow-up (1-2 years) ]
- change in central aortic blood pressure [ Time Frame: from baseline to end of trial follow-up (1-2 years) ]
|Study Start Date:||February 2011|
|Study Completion Date:||September 2012|
|Primary Completion Date:||July 2012 (Final data collection date for primary outcome measure)|
Red Heart Pill Version 1 and Red Heart Pill Version 2.
Drug: Polypill: Red Heart Pill
The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):
Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.
Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2.
Active Comparator: usual medication
participants continuing to receive cardiovascular disease medications as separate tablets prescribed by their usual physician
Drug: Usual medication
Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
Other Name: Usual cardiovascular disease prevention medication
PESCA is a substudy of the UMPIRE clinical trial which is evaluating a 'polypill' treatment strategy for subjects with established cardiovascular disease or at high risk. All PESCA subjects will have already been recruited to UMPIRE and randomised to taking either a single 'polypill' (comprising low dose aspirin, a cholesterol-lowering statin, and one of two blood pressure lowering medicines) or their usual treatment consisting of similar medication in more than one separate tablets.
PESCA will evaluate whether: 1) progression of atherosclerosis (fatty deposits which narrow the arteries and impair blood flow to vital organs); and 2) central systolic blood pressure (the pressure in the body's main artery, the aorta, when the heart pumps out blood), are reduced in 'polypill' recipients compared to those who continue their usual treatment. Atherosclerosis and central blood pressure are both strongly associated with increased risk of heart attacks and stroke. Atherosclerosis will be assessed by ultrasound scanning of the carotid (neck) arteries to look at thickness of the artery walls (carotid intima media thickness)and plaques(fatty deposits). Direct measurement of central blood pressure is impractical but it will be estimated using a computerised "pulsecor" device. This uses an inflatable cuff on the arm but provides a detailed recording of the pressure wave as the cuff is deflated which enables "pulsecor" to calculate central blood pressure. Results from both ultrasound and blood pressure investigations will be reviewed by investigators who do not know whether the subjects have been randomised to the polypill or their usual treatment.
PESCA assessments will be conducted at 2 visits:baseline (as soon as possible after recruitment to the UMPIRE study); and at the end of both studies (which will coincide).
Parallel studies are being undertaken in the three European sites (UK, Eire and Netherlands) participating in the UMPIRE trial with each site aiming to recruit 300 participants.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01326676
|Royal College of Surgeons of Ireland Research Institute|
|University Medical Centre Utrecht|
|Imperial College London|
|London, United Kingdom, W2 1LA|
|Principal Investigator:||Simon McG Thom||Imperial College London|
|Principal Investigator:||Alice Stanton||Royal College of Surgeons in Ireland|
|Principal Investigator:||Michiel Bots||UMC Utrecht|
|Principal Investigator:||Alun Hughes||Imperial College London|